4//SEC Filing
CymaBay Therapeutics, Inc. 4
Accession 0001179110-15-012232
CIK 0001042074operating
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 5:27 PM ET
Size
9.5 KB
Accession
0001179110-15-012232
Insider Transaction Report
Form 4
von Emster Kurt
Director
Transactions
- Purchase
Common stock
2015-08-14$2.70/sh+58,641$158,313→ 90,000 total - Purchase
Common Stock
2015-08-13$2.68/sh+31,359$84,161→ 31,359 total
Holdings
- 1,600,000(indirect: See footnote)
Common Stock
- 17,326(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.675 to $2.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.68 to $2.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F3]Consists of (i) 533,333 shares held by Abingworth Bioventures VI, LP ("ABV VI"), and (ii) 1,066,667 shares held by Abingworth Bioequities Master Fund Limited ("ABE," and collectively with ABV VI, the "Abingworth Funds").
- [F4]Abingworth LLP ("ALLP") provides advisory services to the Abingworth Funds. Kurt von Emster ("Emster") is a member of ALLP. Emster may be deemed the indirect beneficial owner of the shares through his indirect interest in the Abingworth Funds. Emster disclaims beneficial ownership of the shares except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that ALLP, the Abingworth Funds, Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
CymaBay Therapeutics, Inc.
CIK 0001042074
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001042074
Filing Metadata
- Form type
- 4
- Filed
- Aug 16, 8:00 PM ET
- Accepted
- Aug 17, 5:27 PM ET
- Size
- 9.5 KB